This post was originally published on this site
Biogen announced earnings per share of $5.25 on revenue of $2.59B. Analysts polled by Investing.com anticipated EPS of $4.13 on revenue of $2.49B.
Biogen shares are down 8% from the beginning of the year, still down 37.40% from its 52 week high of $351.86 set on August 18, 2021. They are outperforming the Nasdaq 100 which is down 24.94% from the start of the year.
Biogen’s report follows an earnings beat by UnitedHealth on Friday, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on Tuesday with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.55 on revenue of $23.8B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
